Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Raw Materials: 2016-2024

Historic Raw Materials for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $12.5 million.

  • Collegium Pharmaceutical's Raw Materials rose 98.31% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 98.31%. This contributed to the annual value of $12.5 million for FY2024, which is 20.68% up from last year.
  • Collegium Pharmaceutical's Raw Materials amounted to $12.5 million in FY2024, which was up 20.68% from $10.4 million recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Raw Materials registered a high of $12.5 million during FY2024, and its lowest value of $3.5 million during FY2020.
  • Its 3-year average for Raw Materials is $9.5 million, with a median of $10.4 million in 2023.
  • Data for Collegium Pharmaceutical's Raw Materials shows a peak YoY surged of 342.01% (in 2020) over the last 5 years.
  • Collegium Pharmaceutical's Raw Materials (Yearly) stood at $3.5 million in 2020, then increased by 4.87% to $3.7 million in 2021, then skyrocketed by 51.97% to $5.6 million in 2022, then surged by 85.43% to $10.4 million in 2023, then grew by 20.68% to $12.5 million in 2024.